Erdafitinib in locally advanced or metastatic urothelial carcinoma Y Loriot, A Necchi, SH Park, J Garcia-Donas, R Huddart, E Burgess, ... New England Journal of Medicine 381 (4), 338-348, 2019 | 1040 | 2019 |
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial RJ Motzer, TE Hutson, H Glen, MD Michaelson, A Molina, T Eisen, ... The lancet oncology 16 (15), 1473-1482, 2015 | 971 | 2015 |
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3 … BI Rini, T Powles, MB Atkins, B Escudier, DF McDermott, C Suarez, ... The Lancet 393 (10189), 2404-2415, 2019 | 860 | 2019 |
Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4 J Albanell, J Codony, A Rovira, B Mellado, P Gascón New Trends in Cancer for the 21 st Century: Proceedings of the International …, 2003 | 324 | 2003 |
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre … J Garcia-Donas, E Esteban, LJ Leandro-García, DE Castellano, ... The lancet oncology 12 (12), 1143-1150, 2011 | 287 | 2011 |
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution … V Conteduca, D Wetterskog, MTA Sharabiani, E Grande, ... Annals of Oncology 28 (7), 1508-1516, 2017 | 258 | 2017 |
Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study J Aparicio, JR Germà, XG del Muro, P Maroto, JA Arranz, A Sáenz, ... Journal of clinical oncology 23 (34), 8717-8723, 2005 | 249 | 2005 |
Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results P Sharma, A Siefker-Radtke, F de Braud, U Basso, E Calvo, P Bono, ... Journal of Clinical Oncology 37 (19), 1608, 2019 | 202 | 2019 |
Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. B Mellado, D Colomer, T Castel, M Munoz, E Carballo, M Galan, ... Journal of clinical oncology 14 (7), 2091-2097, 1996 | 200 | 1996 |
Interleukin 6, a nuclear factor-κB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-κB inhibition by PS-1145 enhances … J Domingo-Domenech, C Oliva, A Rovira, J Codony-Servat, M Bosch, ... Clinical cancer research 12 (18), 5578-5586, 2006 | 199 | 2006 |
Activation of nuclear factor-κB in human prostate carcinogenesis and association to biochemical relapse J Domingo-Domenech, B Mellado, B Ferrer, D Truan, J Codony-Servat, ... British journal of cancer 93 (11), 1285-1294, 2005 | 165 | 2005 |
Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer M Marín-Aguilera, J Codony-Servat, Ò Reig, JJ Lozano, PL Fernández, ... Molecular cancer therapeutics 13 (5), 1270-1284, 2014 | 162 | 2014 |
Telomerase activity is repressed during differentiation of maturation-sensitive but not resistant human tumor cell lines J Albanell, W Han, B Mellado, R Gunawardane, HI Scher, E Dmitrovsky, ... Cancer Research 56 (7), 1503-1508, 1996 | 161 | 1996 |
Immunohistochemical staining for p16 and p53 in premalignant and malignant epithelial lesions of the vulva M Santos, C Montagut, B Mellado, Á García, SR y Cajal, A Cardesa, ... International journal of gynecological pathology 23 (3), 206-214, 2004 | 139 | 2004 |
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast … J Bellmunt, JL Gonzalez-Larriba, C Prior, P Maroto, J Carles, ... Annals of oncology 22 (12), 2646-2653, 2011 | 129 | 2011 |
Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells J Codony-Servat, MA Tapia, M Bosch, C Oliva, J Domingo-Domenech, ... Molecular cancer therapeutics 5 (3), 665-675, 2006 | 122 | 2006 |
KIT expression in chromophobe renal cell carcinoma: comparative immunohistochemical analysis of KIT expression in different renal cell neoplasms A Petit, M Castillo, M Santos, B Mellado, JB Alcover, C Mallofré The American journal of surgical pathology 28 (5), 676-678, 2004 | 122 | 2004 |
Identification of docetaxel resistance genes in castration-resistant prostate cancer M Marín-Aguilera, J Codony-Servat, SG Kalko, PL Fernández, R Bermudo, ... Molecular cancer therapeutics 11 (2), 329-339, 2012 | 116 | 2012 |
CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA R Molina, X Filella, JM Augé, E Bosch, A Torne, J Pahisa, JA Lejarcegui, ... Anticancer research 25 (3A), 1765-1771, 2005 | 113 | 2005 |
Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: An alternative therapy M Nogué‐Aliguer, J Carles, A Arrivi, O Juan, L Alonso, A Font, B Mellado, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2003 | 113 | 2003 |